Estrogen replacement therapy and breast cancer: Analysis of age of onset and tumor characteristics

Annals of Surgical Oncology

Volumn 6, Issue 2, 1999, Pages 200-207

  Bilimoria, Malcolm M ^a   Winchester, David J ^a   Sener, Stephen F ^a   Motykie, Gary ^a   Sehgal, Uday L ^a   Winchester, David P ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Estrogen; Hormone replacement therapy Breast cancer

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE;

ADULT; AGED; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GRADING; CANCER RISK; CELL CYCLE S PHASE; CELL TYPE; CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DRUG UTILIZATION; ESTROGEN THERAPY; FAMILY HISTORY; FEMALE; HISTOPATHOLOGY; HORMONE RESPONSE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; ONSET AGE; PLOIDY; TUMOR VOLUME;

EID: 0032911246     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0200-7     Document Type: Article

References (42)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. 1997. CA Cancer J Clin 1997;47:5-27.
2. Bilimoria MB, Morrow M. Women at increased risk for breast cancer: evaluation and management strategies. CA Cancer J Clin 1995;45:263-78.
3. Morrow M, Jordan VJ. Risk factors and the prevention of breast cancer with tamoxifen. Cancer Surv 1993;18:211-29.
4. Ross RK, Paginini-Hill A, Gerkins, et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA 1980;243-1635-9.
5. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
6. Elston CW. The assessment of histological differentiation in breast cancer. Aust N Z J Surg 1984;55:11-5.
7. Merkel DE, Winchester DJ, Goldschmidt RA, et al. DNA flow cytometry and pathologic grading as prognostic guides in axillary lymph node-negative breast cancer. Cancer 1993;72:1926-32.
8. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972;48:605-13.
9. Mohle-Boetani JC, Grosser S, Whittemore AS, et al. Body size, reproductive factors, and breast cancer survival. Prev Med 1988; 17:634-42.
10. Lees AW, Jenkins JH, May CL, et al. Risk factors and 10-year breast cancer survival in Northern Alberta. Br Cancer Res Treat 1989;13:143-51.
11. Key TJA, Pike MC. The dose-effect relationship between unopposed oestrogens and endometrial mitotic rate: its central role in predicting endometrial cancer risk. Br J Cancer 1988;57:205-12.
12. Armstrong BK. Oestrogen therapy after the menopause: boon or bane? Med J Aust 1988;148:213-4.
13. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67-72.
14. Stanford JL, Weiss NS, Voigt LF, et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.
15. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-90.
16. Sillero-Arenas M, Delgado-Rodriguez M, Rodriguez-Canteras R, et al. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992;79:286-94.
17. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-80.
18. Steinberg KK, Smith SJ, Thacker SB, et al. Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology 1994;5:415-21.
19. Dupont WD. Estrogen replacement therapy and risk of breast cancer. JAMA 1991;265:1824.
20. Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 1996;38:325-34.
21. Brinton LA, Hoover R, Fraumeni JF. Menopausal estrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986;54:825-32.
22. Van Gils CH, Otten JDM, Verbeek ALM, et al. Breast parenchymal patterns and their changes with age. Br J Radiol 1995;68: 1133-5.
23. Kaufman Z, Garstin WIH, Hayes R, et al. The mammographic parenchymal patterns of women on hormone replacement therapy. Clin Radiol 1991;43:389-92.
24. Berkowitz JE, Gatewood OMB, Goldblum LE, et al. Hormone replacement therapy: mammographic manifestations. Radiology 1990;174:199-201.
25. Stomper PC, Van Voorhid BJ, Ravnikar VA, et al. Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study. Radiology 1990;174:487-90.
26. Cyrlak D, Wong CH. Mammographic changes in postmenopausal women undergoing hormone replacement therapy. Am J Radiol 1993;161:1177-83.
27. Doyle GJ, McLean L. Unilateral increase in mammographic density with hormone replacement therapy. Clin Radiol 1994;49: 50-1.
28. Litherland JC, Evans AJ, Wilson AM. The effect of hormone replacement therapy on recall rate in the National Health Service Breast Screening Programme. Clin Radiol 1997;52:276-9.
29. Tavani A, Braga C, La Vecchia C, Negri E, Franceschi S. Hormone replacement treatment and breast cancer risk: an age-specific analysis. Cancer Epidemiol Biomarkers Prev 1997;6:11-4.
30. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. I. Lancet 1992;339:1-15.
31. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. II. Lancet 1992;339:71-85.
32. Potter JD, Cerhan JR, Sellers TA, et al. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many different kinds of breast cancer are there? Cancer Epidemiol Rev 1993;4:319-26.
33. Allegra JC, Lippman ME, Thompson EB, et al. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res 1979;39:1447-54.
34. Kuukasjarvi T, Kononen J, Helin H, et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996;14:2584-9.
35. Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: five-year observations concerning lobular carcinoma in situ. Cancer 1996;78:1403-16.
36. Bonnier P, Romain S, Giacalone PL, et al. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995;85: 11-7.
37. Schairer C, Byrne C, Keyl PM, et al. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer. Cancer Causes Control 1994;5:491-500.
38. Squitieri R, Tartter PI, Ahmed S, Brower ST, Theise ND. Carcinoma of the breast in postmenopausal hormone user and nonuser control groups. J Am Coll Surg 1994;178:167-70.
39. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurse's Health Study. N Engl J Med 1991;325:756-62.
40. Barrett-Connor E, Bush TL. Estrogen replacement and coronary heart disease. Cardiovasc Clin 1989;19:159-72.
41. Kiel DP, Felson DT, Anerson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women: the Framingham Study. N Engl J Med 1987;317:1169-74.
42. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997;277:1140-7.